1 terminated. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
Follow Thomas Olencki: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer PEG-interferon alfa-2b, Sorafenib, gene expression analysis - Kidney Cancer | Phase 1 | Terminated | Thomas Olencki | 1 | 2008-02-01 | 2015-06-08 |
Carcinoma, Renal Cell (1) · Kidney Neoplasms (1)
Flow Cytometry (1) · Gene Expression Profiling (1) · Immunoenzyme Techniques (1) · Polymerase Chain Reaction (1) · Reverse Transcriptase Polymerase Chain Reaction (1) · Sorafenib (1) · peginterferon alfa-2b (1)
United States (1)